Company intelligence / Profile preview

MOMO Biotech

London, England, United Kingdommomobio.tech ↗

Ownership: Private
Development stage: Preclinical

Overview

MOMO Biotech has developed TMEmic, a proprietary tumour-on-a-chip device that more accurately recapitulates the tumour microenvironment for solid tumours. This enables improved preclinical testing of oncology drug candidates and aims to help biotechs de-risk assets before entering clinical trials. No direct clinical results, as the company provides enabling technology rather than therapeutics

Therapeutic areas: Oncology
Modalities: Device (tumour-on-a-chip)Software/bioinformatics workflow
Industry: Drug Discovery Services

Beyond the preview

Go deeper on MOMO Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MOMO Biotech.

Explore the full profile